Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback